1. Greenberg PL, Cox C, LeMeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J . International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 1997 89: 2079–2088
2. Aul C, Gattermann N, Schneider W . Age-related incidence and other epidemiological aspects of myelodysplastic syndrome Br J Haematol 1994 87: 743–745
3. De Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M, Solbou G, Zwierzina H, Muus P . Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute leukemia following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of European Organization for Research and Treatment in Cancer (EORTC-LCG) Leukemia 1995 9: 1805–1811
4. Gassmann W, Schmitz N, Loffler H, De Witte T . Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes Semin Hematol 1996 33: 196–205
5. Yaguchi M, Miyazawa K, Katagiri T, Nishimaki J, Kizaki M, Tohyama K, Toyama K . Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid Leukemia 1997 11: 779–787